Navigation Links
Clarient Generates 52% Revenue Increase in Third Quarter 2007
Date:10/30/2007

ntinuing

operations (2,914) (3,112) (9,759) (10,212)

Income (loss) from

discontinued operations,

net of tax 153 (838) 5,514 (2,331)

Net loss $(2,761) $(3,950) $(4,245) $(12,543)

Basic and diluted income

(loss) per common share:

Continuing operations $(0.04) $(0.05) $(0.14) $(0.15)

Discontinued operations $0.00 $(0.01) $0.08 $(0.04)

Net Income (loss) $(0.04) $(0.06) $(0.06) $(0.19)

Weighted average number

of common shares

outstanding 71,613,956 67,339,694 71,482,084 67,007,971

Clarient , Inc.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

September 30, December 31,

2007 2006

Cash and cash equivalents $1,994 $448

Accounts receivable, net 11,604 8,851

Property and equipment, net 10,909 10,138

Other assets 2,164 7,593

Total assets $26,671 $27,030

Total liabilities $27,668 $25,870

Stockholders' equity (997) 1,160

Total liabilities and stockholders' equity $26,671 $27,030


'/>"/>
SOURCE Clarient, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Kylie generates awareness about mammography
2. Health Insurance Scheme Generates Conflicting Opinions
3. Stem Cell Therapy Regenerates Heart Muscle In Heart Attack Patients
4. Body generates Antibiotic against Urinary Tract Infection
5. Soy Protein Study Generates New Findings
6. Dairy Farmers, Cheesed Off Over Revenue Loss from WIC Program
7. Use of Cellular Phones associated with Increased risk of Brain Tumors
8. Mortality increased in Sporting enthusiasts!
9. Tattoos may significantly increase risk of hepatitis C infection
10. Increase in sugar...decrease in brain function!!!
11. Increase in tobacco deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...stCall/ -- Universal Health,Realty Income Trust (...ded their,Board of Trustees with the appointment ...rsal Health Services, Inc. (UHS). Mr. Miller brin...lthcare leadership roles. He has,served as UHS, ...e Division,since 2007 and prior to that, served a...
(Date:12/4/2008)...ant gene could ease sickle-cell disease and thalas...4, 2008 -- Researchers at Children,s Hospital Bost...ancer Institute have identified a way to get red b...y made only before birth or by young infants. This...nd beta-thalassemia -- life-threatening inherited ...
(Date:12/4/2008)...en Joffe, Craig Joffe, and,Alan Buckey today file...,Securities and Exchange Commission. The group p...4% of LCA-Vision, Inc. (Nasdaq: LCAV ), which,o...ction centers in 33 states,in the United States. ...CEO of,LCAV. Craig Joffe is the former Chief Ope...
(Date:12/4/2008)..." , , WASHINGTON, Dec. 4 /PRNewswire-USNews...into question the safety of the Centers for Diseas...dministering multiple vaccines concurrently. , ...sorder Patients, published last week in PLOS One ...Hopkins Kennedy Krieger Institute and Massachusett...
Breaking Medicine News(10 mins):Health News:Turning back the Clock in Inherited Anemias 2Health News:Turning back the Clock in Inherited Anemias 3Health News:Turning back the Clock in Inherited Anemias 4Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 2Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 3Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 4Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 5Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 6Health News:Researchers & Department of Defense Question Multiple Vaccine Administration 2
...gs from a recent study researchers say, the ancien...cal application. Lymphoma patients// who took part...n those in a control group. The study was conducte...ther undergoing treatment or who had concluded tre...
...extended exposure to sunlight may lead to age-rela...egeneration an eye // disorder that can cause blin...ts for five years and more than 2,700 patients for...86 years old. Participants who reported being in t...
...s( DVT ) is a blood clot that develops deep in the...lung. // People who require prolonged bed rest ar... blood circulation ,especially patients in intensi...a serious risk for DVT. Recent studies have shown ...
...w individuals in lower socioeconomic groups, as me...ul days than those with // higher socioeconomic st...rger impact on their health. While those with more...y are not as affected by it. For the study, more t...
Other Medicine News:
(Date:12/2/2008)...wire-FirstCall/ -- Biopure Corporation,(Nasdaq: ...l Research Center,(NMRC) has submitted to the Foo...gational new drug (IND) application to conduct a c... Hemopure(R) [hemoglobin glutamer - 250 (bovine)],...uma patients. The study is,entitled "Operation Re...
(Date:12/2/2008).../ -- Horizon Therapeutics, Inc., a,privately held...wo pivotal,Phase 3 trials evaluating its lead inv...primary endpoints. HZT-501, a novel, proprietary f...n and famotidine, demonstrated a,statistically si...dal,anti-inflammatory drug (NSAID)-induced upper ...
(Date:12/1/2008)...2 A study has found tha...ique for imaging the breast, is not affected by ei...two factors that limit the effectiveness of standa...s will be presented today at the annual meeting of... , , "The ability of PEM to detect cancer ...
(Date:12/1/2008)...- S*BIO Pte Ltd today announced the initiation of ... orally-active JAK2 inhibitor, in leading medical ...opathic myelofibrosis (CIMF). , , The tria...ity of SB1518 in patients with CIMF and is expecte... the study will assess the safety profile and eval...
Breaking Medicine Technology:U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 2U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Minorities More Likely to Die in ER 27526 1Minorities More Likely to Die in ER 27526 2Minorities More Likely to Die in ER 27526 3Coleman Natural 28R 29 Foods Launches New and Improved Website 27523 1Coleman Natural 28R 29 Foods Launches New and Improved Website 27523 2Douglas Oberhelman Elected to Lilly Board of Directors 8390 1Douglas Oberhelman Elected to Lilly Board of Directors 8390 2Douglas Oberhelman Elected to Lilly Board of Directors 8390 3Sandia SES win Popular Mechanics Breakthrough Innovator Award 5467 1Sandia SES win Popular Mechanics Breakthrough Innovator Award 5467 2
...DGE, Mass.--(BUSINESS WIRE)--Mar 26, 2007 - Combin... preliminary results of,a phase 2 clinical trial s...prednisolone and the antidepressant paroxetine),an...oid arthritis,(RA). This trial served two importan...t of 3mg of prednisolone alone (a very low dose),i...
...Y, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Inotek,P...sentation of,positive Phase 2 clinical data demons...ntial for INO-1001 as a preventative agent for,car...n subjects,with acute ST-elevated myocardial infar...nary intervention. The presentation was,made in a ...
Other Medicine Technology:CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 2CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 3CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 4CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 5CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 6Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 2Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 3Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 4
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
Medicine Products: